Enjoy complimentary customisation on priority with our Enterprise License!
The anti-inflammatory therapeutics market size is forecast to increase by USD 38.7 billion at a CAGR of 6.3% between 2023 and 2028. The market is experiencing significant growth due to several key trends. The increase in off-label use of anti-inflammatory drugs in various indications beyond their approved uses is driving market growth. Additionally, the emergence of novel anti-inflammatory drugs, including monoclonal antibodies and small molecules, is providing new treatment options for inflammatory diseases. Autoimmune diseases, such as RA, and respiratory diseases, like pneumonia, can lead to a cytokine storm, resulting in acute respiratory distress, acute lung injury, and multiple organ dysfunction. However, the market also faces challenges, such as the risks and uncertainties associated with anti-inflammatory biologics, including their high production costs, potential side effects, and complex administration routes. These factors are necessitating the development of more cost-effective and convenient delivery systems to enhance patient compliance and improve market penetration.
Overall, the market is poised for growth, driven by the increasing prevalence of inflammatory diseases and the development of innovative treatments.
Anti-inflammatory therapeutics have gained significant importance in the pharmaceutical industry due to the rising incidence of chronic illnesses, autoimmune diseases, respiratory diseases, infectious illnesses, chronic pain, sprains, menstrual pain, rheumatoid arthritis, migraines, and headaches. These conditions are characterized by inflammation, swelling, and prostaglandin levels that contribute to pain and discomfort. Conventional medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been the primary treatment options for inflammation-related conditions. However, the emergence of anti-inflammatory biologics, including biosimilars, has revolutionized the therapeutic landscape. These advanced treatments target specific cytokines and proteins involved in the inflammatory response, providing effective pain relief and reducing the negative effects associated with conventional medications.
With the patent expiration of key anti-inflammatory biologics, such as Remicade, the market is expected to witness increased competition and innovation. The market is further expected to be influenced by the rising incidence of autoimmune diseases, respiratory diseases, and chronic pain, as well as the current COVID-19 pandemic and its associated complications, including beta coronavirus, pneumonia, and cytokine storm.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The RA segment is estimated to witness significant growth during the forecast period. Anti-inflammatory therapeutics play a significant role in managing various chronic illnesses, including autoimmune diseases and respiratory diseases. Autoimmune diseases, such as rheumatoid arthritis (RA), cause inflammation when the body's immune system mistakenly attacks healthy cells. This results in joint pain, swelling, and stiffness. According to the Centers for Disease Control and Prevention (CDC), approximately 54.4 million adults in the US have arthritis, making it a leading cause of disability. Inflammation is also a common response to infectious illnesses and acute conditions, such as sprains and menstrual pain. Conventional medications, such as corticosteroids, have long been used for pain relief and inflammation reduction.
However, the negative effects of long-term corticosteroid use have led to the development of anti-inflammatory biologics, including biosimilars. The NLRP3 inflammasome plays a crucial role in the inflammatory response, making it a potential target for new anti-inflammatory medications. The global health crisis caused by chronic ailments, including autoimmune disorders and respiratory disorders, has resulted in increased healthcare spending. With the patent expiration of major anti-inflammatory biologics, such as Remicade, the market for anti-inflammatory pharmaceuticals is expected to grow as new medications enter the market.
Inflammation is a complex process involving the production of prostaglandins and other mediators. Understanding the underlying mechanisms of inflammation is crucial for the development of effective anti-inflammatory therapeutics.
Get a glance at the market share of various segments Request Free Sample
The RA segment accounted for USD 47.00 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Inflammatory disorders, including psoriasis, ulcerative colitis, inflammatory bowel diseases, arthritis, asthma, and COPD, among others, are characterized by the activation of immune cells and the release of cytokines. Monoclonal antibodies and janus kinase inhibitors are among the leading therapeutic options for treating autoimmune inflammatory disorders. These medications target specific immune responses and cytokines, providing effective relief for patients. Hospital pharmacies, retail pharmacies, and internet pharmacies are key distribution channels for these therapeutics. E-commerce platforms have also emerged as significant players in the market, enabling easy access to these essential medications for patients with respiratory illnesses, such as asthma and COPD, and those with dermatological conditions, such as atopic dermatitis and psoriasis.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The Increase in off-label use is the key driver of the market. The global market is experiencing significant growth due to the increasing incidence of chronic illnesses, autoimmune diseases, respiratory diseases, and infectious illnesses. These conditions are characterized by inflammation, swelling, and pain, which necessitates the use of anti-inflammatory drugs for pain relief. Conventional medications such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for inflammation reduction. Some anti-inflammatory biologics, including biosimilars, are also gaining popularity due to their efficacy in treating chronic conditions such as rheumatoid arthritis, pneumonia, and cytokine storm-related conditions like acute respiratory distress and acute lung injury. The global population, particularly those suffering from multiple organ dysfunction, is at risk of these chronic ailments, leading to increased healthcare spending.
Moreover, with the patent expiration of some major anti-inflammatory drugs like Remicade, the market is expected to witness the introduction of new medications. However, the negative effects of long-term use of corticosteroids and NSAIDs, such as increased prostaglandin levels and potential side effects, may limit market growth. The NLRP3 inflammasome, a key player in the inflammatory response, is a potential target for new anti-inflammatory pharmaceuticals. The unknown etiology of inflammatory and autoimmune diseases increases the off-label use of various anti-inflammatory drugs, further driving market growth.
The emergence of novel anti-inflammatory drugs is the upcoming trend in the market. Anti-inflammatory therapeutics have gained significant attention in the healthcare industry due to their effectiveness in managing various chronic illnesses, including autoimmune diseases and respiratory diseases. Anti-inflammatory biologics, such as monoclonal antibodies, have revolutionized the treatment landscape by specifically targeting the root cause of inflammation. Biosimilars, which are affordable alternatives to these biologics, have also emerged as a viable option for patients. Chronic illnesses, such as rheumatoid arthritis, pneumonia, and inflammatory bowel diseases, affect a large population and result in high healthcare spending. Conventional medications, like corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), provide pain relief and reduce swelling by modulating prostaglandin levels.
However, they often come with negative effects, such as an increased risk of infections and gastrointestinal issues. The incidence of autoimmune diseases and respiratory diseases continues to rise, fueling the demand for new medications. With patent expiration of blockbuster drugs like Remicade, the market for anti-inflammatory therapeutics is expected to witness significant growth. The NLRP3 inflammasome, a key player in the inflammatory response, has emerged as a promising target for the development of new anti-inflammatory pharmaceuticals. Inflammation, a crucial part of the body's immune response, can lead to acute respiratory distress, acute lung injury, and multiple organ dysfunction in severe cases, such as cytokine storms.
The Risks and uncertainties associated with anti-inflammatory biologics is a key challenge affecting the market growth. Anti-inflammatory therapeutics, including biologics and biosimilars, play a crucial role in managing various chronic illnesses, such as autoimmune diseases, respiratory diseases, and chronic pain. Autoimmune diseases, like rheumatoid arthritis, and inflammatory conditions, such as sprains and menstrual pain, can significantly impact the quality of life. Conventional medications, such as corticosteroids and pain relievers, offer temporary relief from swelling and inflammation by modulating prostaglandin levels. However, the incidence of chronic ailments, including autoimmune disorders and respiratory disorders, continues to rise, leading to increased healthcare spending. The development of anti-inflammatory biologics, such as Remicade, has revolutionized the treatment landscape for several conditions.
However, the complex manufacturing process and stringent regulations pose challenges. Government regulations, including those related to the transport and use of raw materials like cell lines, add to the complexity and uncertainty of the development process. Furthermore, the manufacturing and sale of biologics are subjected to more complex and exhaustive regulations than other pharmaceutical products. The production of large quantities of biologics requires the use of novel technologies and a specially designed manufacturing facility that must be validated for this purpose. The manufacturing procedure must comply with standard norms to produce quality products. The global health crisis, including conditions like pneumonia, cytokine storm, acute respiratory distress, and acute lung injury, highlights the need for new medications to address inflammation. The NLRP3 inflammasome, a key player in the inflammatory response, is a promising target for the development of new anti-inflammatory pharmaceuticals. Despite the challenges, the potential benefits of anti-inflammatory therapeutics in managing chronic ailments make the investment worthwhile.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company specializes in the development and provision of anti-inflammatory therapeutics. These innovative solutions cater to various industries, including sports and fitness.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Anti-inflammatory therapeutics have gained significant importance in the pharmaceutical industry due to the rising incidence of chronic illnesses, autoimmune diseases, respiratory diseases, infectious illnesses, chronic pain, sprains, menstrual pain, rheumatoid arthritis, migraines, and headaches. Conventional medications, such as corticosteroids, have been the mainstay of treatment for inflammation, providing pain relief and reducing swelling by modulating prostaglandin levels. However, these medications come with negative effects, leading to the development of anti-inflammatory biologics. Biosimilars of these biologics, including Remicade, have entered the market, offering cost-effective alternatives. Chronic ailments, autoimmune disorders, and respiratory disorders, such as pneumonia, cytokine storm, acute respiratory distress, and acute lung injury, have become a global health crisis, driving the demand for new anti-inflammatory pharmaceuticals.
The NLRP3 inflammasome has emerged as a potential target for anti-inflammatory therapeutics, offering a new approach to treating inflammation. With patent expiration of several key anti-inflammatory drugs, the market is expected to witness significant growth in the coming years, with healthcare spending on chronic ailments continuing to rise.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
174 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.3% |
|
Market growth 2024-2028 |
USD 38.7 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.81 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key countries |
US, Germany, UK, Canada, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., Cipla Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Ferring BV, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Viatris Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Novartis AG |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.